Raptor pharmaceuticals (RPTP) könnte ein interessanter Zock sein. Am Mittwoch wird über die Zulassung eines Medikaments in den USA und EU entschieden.In March 2012, Raptor applied for marketing approval in the U.S. and E.U. of RP103 for the potential treatment of nephropathic cystinosis. Raptor anticipates decisions from the FDA on April 30, 2013 and the EMA in the second half of 2013. Raptor continues to build out its commercial infrastructure to meet the demands of a potential commercial launch upon marketing approval.Veloci-Raptor time?First up is Raptor Pharmaceuticals (NASDAQ: RPTP ) with Procysbi (previously known as RP-103), its oral delayed and extended-release medication to treat nephropathic cystinosis. In trials, Procysbi proved to be non-inferior to the only other FDA-approved treatment for nephropathic cystinosis, known as Cystagon from Mylan (NASDAQ: MYL ) .As my Foolish colleague Keith Speights has already pointed out, both Procysbi and Cystagon are two different forms of cysteamine bitartate. However, Cystagon comes with the need to be taken four times daily (meaning sleep schedules can and will get interrupted) and has a slew of other potential side effects. Procysbi, on the other hand, needs only to be taken twice daily and has milder side effects.From an ease-of-use standpoint, the drug looks like a slam-dunk for an approval, but the FDA will have to be able to determine that the side effects are diminutive compared to the benefits Procysbi can deliver. If Raptor can get Procysbi approved it would give the company its first revenue generating drug, as well as peak sales potential in the U.S. of $60 million according to JMP Securities. This PDUFA decisions has already been pushed back 90 days to review additional data, so this will certainly be a name to watch on Tuesday.Ich bin drin.Good zock